ASX Announcements

DateTitle
16th May 2017Completion of Development of Glasses-Free 3D ChipDownload
15th May 2017ITL Investor UpdateDownload
12th May 2017Share Consolidation CompletionDownload
10th May 2017Change in Director Interest NoticeDownload
9th May 2017Results of MeetingDownload
2nd May 2017Share Consolidation CommencementDownload
2nd May 2017MyHealthTest Achieves Laboratory AccreditationDownload
28th Apr 2017Appendix 4C - quarterlyDownload
19th Apr 2017ITL awarded Supply Agreement with NZ Blood ServiceDownload
18th Apr 2017Update on Share ConsolidationDownload
7th Apr 2017Notice of Annual General Meeting/Proxy FormDownload
6th Apr 2017Update on Form 20-F for Proposed NASDAQ Dual ListingDownload
3rd Apr 2017Release of 2016 Audited Financial ResultsDownload
3rd Apr 2017Annual Report to shareholdersDownload
3rd Apr 2017Appendix 4GDownload
28th Mar 2017ITL Achieves Record MonthDownload
3rd Mar 2017Results of MeetingDownload
1st Mar 2017Preliminary Final ReportDownload
27th Feb 2017Update on Form 20-F for Proposed Nasdaq Dual ListingDownload
27th Feb 2017ITL Global rebrand to ITL Health GroupDownload
20th Feb 2017ITL Corporate & BioMedical Growth UpdateDownload
20th Feb 2017Boardroom Radio Interview Mr Bill Mobbs CEO ITLDownload
20th Feb 2017Substantial Holding in ITL Notice - TBFDownload
17th Feb 2017ITL Appendix 4D & Financial Statements Dec 2016Download
17th Feb 2017ITL Profit Doubles in Half Year 2016-17 ResultsDownload
2nd Feb 2017Submission of Nasdaq Listing Application FormDownload
2nd Feb 2017Notice of Extraordinary General Meeting/Proxy FormDownload
31st Jan 2017Appendix 4C - quarterlyDownload

MyHealthTest Achieves Major Milestone of Laboratory Accreditation

MyHealthTest (MHT), a division of ITL Health Group (ASX:ITD) that creates and markets highly innovative direct to consumer pathology testing for major chronic diseases, is very pleased to announce it has been granted accreditation for its testing laboratory to the ISO15189 and NPAAC (National Pathology Accreditation Advisory Council) standards by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA).

Read More “MyHealthTest Achieves Major Milestone of Laboratory Accreditation” »

Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update

ITL Limited is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.

Mr Mobbs talks about the Company’s strong first half results that saw revenue rise 11%, EBITDA up 69% and profit before tax grow 110% versus the previous comparative period, and provides an insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.

Read More “Boardroom Media Interview: Strong Half Year Results and ITL BioMedical Update” »

ITL brings on Specialist Small Cap Fund Manager

Founder and Executive Chairman Mr. Bill Mobbs has released a parcel of his 42% of ITL (4.6m shares) to a Specialist Small Cap Fund Manager and to fellow ITL non-executive Director Mr. Mark Peatey. Mr. Mobbs retains 36% of ITL.

Read More

ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2

ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare® Needle Guard 2 will take place at the AABB Annual Meeting in Orlando, the premiere event for healthcare professionals in transfusion medicine and cellular therapies. Read More “ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2” »

ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux

ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries. Read More “ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux” »

5 Year Contract Win with Macquarie University Hospital

ITL Limited, a diversified healthcare company and owner of ITL Healthcare which produces quality invasive blood pressure monitoring systems, is pleased to announce a new five year contract with Macquarie University Hospital (MUH), Australia’s first private not-for-profit teaching hospital, located at Macquarie University in Sydney. Read More “5 Year Contract Win with Macquarie University Hospital” »